A REVIEW ARTICLE ON NANOPARTICLE

 

12. Novel optoelectronic devices
In the modern communication technology traditional analog electrical devices are increasingly replaced by optical or optoelectronic devices due to their enormous bandwidth and capacity, respectively. Two promising examples are photonic crystals and quantum dots.

Photonic crystals are materials with a periodic variation in the refractive index with a lattice constant that is half the wavelength of the light used. They offer a selectable band gap for the propagation of a certain wavelength, thus they resemble a semiconductor, but for light or photons instead of electrons.

13. Displays
The production of displays with low energy consumption could be accomplished using carbon nanotubes (CNT). Carbon nanotubes can be electrically conductive and due to their small diameter of several nanometers, they can be used as field emitters with extremely high efficiency for field emission displays (FED). The principle of operation resembles that of the cathode ray tube, but on a much smaller length scale. (13)

Toxicological hazards of nanoparticles

General concepts
To use the potential of Nanotechnology in Nanomedicine, full attention is needed to safety and toxicological issues. For pharmaceuticals specific drug delivery formulations may be used to increase the so called therapeutic ratio or index being the margin between the dose needed for clinical efficacy and the dose inducing adverse side effects (toxicity). However, also for these specific formulations a toxicological evaluation is needed. This is particularly true for the applications of nanoparticles for drug delivery. In these applications particles are brought intentionally into the human body and environment, and some of these new applications are envisaged an important improvement of health care .Opinions started to divert when toxicologists claimed that new science, methods and protocols are needed .However, the need for this is now underlined by several and more importantly by the following concepts:

  1. Nanomaterials are developed for their unique (surface) properties in comparison to bulk materials. Since surface is the contact layer with the body tissue, and a crucial determinant of particle response, these unique properties need to be investigated from a toxicological standpoint. When nanoparticles are used for their unique reactive characteristics it may be expected that these same characteristics also have an impact on the toxicity of such particles. Although current tests and procedures in drug and device evaluation may be appropriate to detect many risks associated with the use of these nanoparticles, it cannot be assumed that these assays will detect all potential risks. So, additional assays may be needed. This may differ depending on the type of particles used, ie, biological versus non-biological origin.
  2. Nanoparticles are attributed qualitatively different physico-chemical characteristics from micron-sized particles, which may result in changed body distribution, passage of the blood brain barrier, and triggering of blood coagulation pathways. In view of these characteristics specific emphasis should be on investigations in (pharmaco)kinetics and distribution studies of nanoparticles. What is currently lacking is a basic understanding of the biological behavior of nanoparticles in terms of distribution in vivo both at the organ and cellular level.
  3. Effects of combustion derived nanoparticles in environmentally exposed populations mainly occur in diseased individuals. Typical pre-clinical screening is almost always done in healthy animals and volunteers and risks of particles may therefore be detected at a very late stage.

The use of nanoparticles as drug carrier may reduce the toxicity of the incorporated drug. In general the toxicity of the whole formulation is investigated while results of the nanoparticles itself are not described. So, discrimination between drug and nanoparticle toxicity cannot be made. So, there should be a specific emphasis on the toxicity of the “empty” non-drug loaded particles. This is especially important when slowly or non degradable particles are used for drug delivery which may show persistence and accumulation on the site of the drug delivery, eventually resulting in chronic inflammatory reactions.(14)

REFERENCE:
1.Wim H De Jong1 and Paul JA Borm2,3
1Laboratory for Toxicology, Pathology and Genetics, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
2Zuyd University, Centre of Expertise in Life Sciences, Heerlen, The Netherlands
3Magnamedics GmbH, Aachen, Germany
2.. Nanoparticles-Targeting Neurotherapeutic Agents Through The Blood Brain Barrier,Shivakumar H.G, Gowda D.V, Krishna R.S.M, Das. D.
3. Panayam, J.; Labhasetwar, V. Curr. Drug Deliv.2004, 1, 235.
4. Attard, G. S.; Bartlett, P. N.; Coleman, N. R. B.; Elliot, J. M.; Owen, J. R.; Wang, J.H. Science 1997, 278, 838.
5. Wang, C., Shim, M. & Guyot-Sionnest, P. Electrochromic nanocrystal quantum dots.,Science 291 2390-2392 (2001).
6. "Peter Weiss". Quantum-Dot Leap.Science News Online. Retrieved on 2005-06-17
7. May, P. M.; Bulman, R. A. Prog. Med. Chem. 1983, 20, 225. 2962 A. H. Faraji, P. Wipf / Bioorg. Med. Chem. 17 (2009) 2950–2962
a.Jana, S, Chakraborty, C, Nandi, S and Deb, JK (2004). RNA interference: potential therapeutic targets. Appl Microbiol Biotechnol 65: 649–657.
b.Li, SD and Huang, L (2006). Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther 13: 1313–1319.
c.Li, W and Szoka, FC Jr. (2007). Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 24: 438–449.
8.Robson, T. 1., Worthington, J., McKeown, S. R., Hirst, D. G. Radiogenic Therapy: Novel Approaches for Enhancing Tumor Radiosensitivity.TCRT 4, 343-362 (2005)
9.Salem II, Flasher DL, Duzgunes N. Liposome-encapsulated antibiotics. Methods Enzymol 2005;391:261–291.
10.system against experimental tuberculosis Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 2005;55:430–435.
11.Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52:981–986.
12. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70: 1–20, 2001. [PubMed]
13. Wang, C., Shim, M. & Guyot-Sionnest, P. Electrochromic nanocrystal quantum dots.,Science 291 2390-2392 (2001).
a. "Peter Weiss". Quantum-Dot Leap.Science News Online. Retrieved on 2005-06-17
b.Electric Field Assisted Assembly of Functionalized Quantum Dots into Multiple Layer Thin Films
D.A. Dehlinger, B.D. Sullivan, S. Esener and M.J. Heller.
c.Yamakoshi Y, Umezawa N, Ryu A, et al. Active oxygen species generated from photo-excited fullerene (C-60) as potential medicines: O2− versus 1O2 . J Am Chem Soc. 2003;125:12803–9.
14.Zhang L, Hu Y, Jiang X, et al. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J Control Release. 2004;96:135–48.
14a.Zhu S, Oberdörster E, Haasch ML. Toxicity of an engineered nanoparticle (fullerene, C60) in to aquatic species, Daphnia and flathead minnow. Mar Environ Res. 2006;62(Suppl):S5–9.

NOW YOU CAN ALSO PUBLISH YOUR ARTICLE ONLINE.

SUBMIT YOUR ARTICLE/PROJECT AT articles@pharmatutor.org

Subscribe to Pharmatutor Alerts by Email

FIND OUT MORE ARTICLES AT OUR DATABASE


Pages

FIND MORE ARTICLES